Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line data from this study are expected by the end of 2024.Enrollment in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC) was completed in the first quarter of 2024; top-line data from Stage 1 of this study are expected by mid-year 2024. Initiated planning of a Phase 2 monot ...

文章核心观点 - 公司开发的生物特异性检查点抑制剂CTX-8371具有独特的作用机制,可以同时靶向PD-1和PD-L1,并诱导细胞表面PD-1的蛋白水解性切割和丢失 [1][2] - CTX-8371相比已上市的抗PD-1和抗PD-L1疗法在体外和体内实验中表现出更强的抗肿瘤活性 [2][3] - CTX-8371与公司的CD137激动性抗体CTX-471的组合在小鼠肿瘤模型中进一步增强了抗肿瘤疗效 [3] 公司概况 - 公司是一家临床阶段的肿瘤生物制药公司,专注于开发自主研发的抗体类治疗药物 [3] - 公司的科学重点是探讨血管生成、免疫系统和肿瘤生长之间的关系 [3] - 公司的产品管线针对多个关键生物通路,包括通过针对血管生成的靶向药物调节微血管,通过激活肿瘤微环境中的效应细胞诱导强大的免疫反应,以及缓解肿瘤逃逸免疫监视的免疫抑制机制 [3] - 公司计划根据临床和非临床数据,将产品候选药物作为单独疗法或与公司管线中的抗体组合用药推进临床开发 [3] 临床进展 - 公司的生物特异性抗体CTX-8371的IND申请已于2023年底获得FDA批准,预计将在本季度内给首例患者给药 [3]

盈利预期和评级 - Compass Therapeutics, Inc.最近被升级为Zacks Rank 2 (Buy)，这是因为其盈利预期呈上升趋势[1] - Zacks评级系统主要依赖于公司盈利前景的变化，通过跟踪卖方分析师对当前和未来年度的EPS预测来进行评级[2] - Compass Therapeutics, Inc.的盈利预期上升和评级升级基本上意味着公司基础业务的改善，投资者对这一改善的业务趋势的认可应推动股价上涨[6] 盈利预期修订 - Compass Therapeutics, Inc.的盈利预期修订表明公司预计在2023年12月的财政年度将每股亏损0.33美元，同比增长10.8%[9] - 过去三个月，分析师们一直在稳步提高对Compass Therapeutics, Inc.的盈利预期，公司的Zacks Consensus Estimate增长了2.3%[10] Zacks评级系统 - 机构投资者使用盈利和盈利预测来计算公司股票的公允价值，盈利预测的增加或减少会直接影响股票的公允价值，从而引发股价的波动[5] - Zacks评级系统有效利用盈利预测修订的力量，因此跟踪这些修订以做出投资决策可能会带来实质性回报[7] - Zacks评级系统保持了对超过4000只股票的'买入'和'卖出'评级的平等比例，只有Zacks覆盖的股票中的前5%获得'Strong Buy'评级，接下来的15%获得'Buy'评级，因此公司被列入Zacks覆盖的股票前20%意味着其具有优秀的盈利预期修订特性，有望在短期内产生超越市场的回报[11]

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 As of November 3, 2023, the registrant had 127,486,326 shares of common stock, $0.0001 par value per share, outstanding. FORM 10-Q | --- | --- | |------------------------------------------------------------------------------------------------------------|-----------------------------------------------------| | | | | Commission File Number: | 001-39696 | | COMPASS THERAPEUTICS, INC. (Exact Name of Registrant as | Specifi ...

The following discussion of the financial condition and results of operations of Compass Therapeutics, Inc. should be read in conjunction with the financial statements and the notes to those statements included in this Quarterly Report on Form 10-Q for the three and six month periods ended June 30, 2023. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risk, uncer ...

公司产品 - Compass Therapeutics, Inc. 是一家致力于开发专有抗体类治疗药物的临床阶段生物制药公司[45] - CTX-009 是一种抗DLL4 x VEGF-A双特异性抗体，目前正在美国、韩国和中国的患有晚期实体瘤的患者中进行临床开发[46] - CTX-471 是一种CD137的单克隆抗体激动剂，已在小鼠模型中展现出对肿瘤微环境的显著影响[56] - CTX-8371 是一种同时靶向PD-1和PD-L1的双特异性抗体，已在小鼠模型中表现出优于PD-1、PD-L1或两者联合治疗的能力[65] - Compass Therapeutics 与 Merck & Co. 合作评估CTX-471与KEYTRUDA（pembrolizumab）的联合应用，旨在恢复患者对PD-1或PD-L1检查点抑制剂治疗的反应[62] 资金情况 - 截至2023年3月31日，Compass Therapeutics 通过出售股权证券融资主要资助了其运营，总共获得了4.09亿美元的募集资金[67] - 公司在2023年3月31日的三个月内运营亏损为7,837,000美元，较去年同期的7,162,000美元有所下降[76] - 公司在2023年3月31日的三个月内投资活动中获得了4,269,000美元的现金，主要来自于市场证券[85] - 公司截至2023年3月31日，现金、现金等价物和市场证券总额为175,000,000美元[80] - 公司预计未来的资金需求将主要用于研发支出，包括临床试验、产品制造和商业化等方面[81] - 公司相信目前的现金储备可以支持其运营支出和资本支出至2026年[88] 研发支出 - 研发支出主要包括与CTX-471、CTX-8371和CTX-009的开发相关的成本，如员工薪酬、与支持平台项目开发的组织的协议费用、合同制造组织的费用等[70] - 研发支出在2023年3月31日的三个月内增加了2,223,000美元，达到6,638,000美元，同比增长50%[76] - 总体而言，公司的研发支出主要用于CTX-009项目，该项目在2023年3月31日的三个月内花费了3,916,000美元[77] 内部控制 - 公司的管理层认为截至2023年3月31日，其披露控制和程序是有效的[90] - 公司在2023年第一季度没有发生对财务报告内部控制的重大变化[91]

Medicines can be authorized in the European Union by using either the centralized authorization procedure or national authorization procedures. 42 National authorization procedures. There are also two other possible routes to authorize medicinal products in several European Union countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure: Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in on ...

Corporate Presentation December 2022 SRC DISCLAIMER This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes ava ...

Corporate Presentation November 2022 SRC DISCLAIMER This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes ava ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-39696 COMPASS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) D ...